Right. Good morning. Welcome to the Jefferies Healthcare conference in London. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having Ardelyx here with us. Welcome. Maybe I'll kick it off with just kind of like a big picture question. Maybe just talk about the progress you guys have made this year on both IBSRELA and XPHOZAH, and just how you're thinking about the outlook.
Sure. First, Dennis, thank you and Jefferies for inviting us. It's great to be here. I think as we exit 2026 and into 2027, it's an incredibly important pivotal transition for the company. I think as you heard this year, and we reinforced in the Q3 earnings, next year is when we're going to pivot into profitability. Certainly for us, as we look at the impact that IBSRELA, which we refer to as the engine of the future of what we're doing at Ardelyx, its continued performance and the benefit it's providing patients is really driving us in what we ultimately aspire to accomplishing. We're right on that cusp of that transition.
I think that time is a critical one for us as we look exiting 2026 with the performance we've seen this year, and the benefit that we're going to see next year as a result of that.
Okay. As it relates to underlying demand for IBSRELA, what are you seeing on the ground? Then we can certainly talk about-
Sure
some of the other access.
I mean, if you take a step back, you look at the number of prescriptions that are written for IBS-C indicated medications, about 7 million-8 million prescriptions. The underlying demand for IBSRELA and the opportunity there is significant, right? We know that 70% or more of patients that are on the current drugs are under-satisfied, not well treated by those medications that are there, leaving only IBSRELA as an option for them. The opportunity is quite significant. As we announced also in Q3, we fully enrolled our chronic idiopathic constipation trial, which is an important indication as it then allows a clinician to not have to differentiate between CIC and IBS-C when prescribing a medication like IBSRELA.
Again, as you look at those top line reading out in the second half of next year, another really important pivotal point for the company as that TAM will then increase by the number of CIC patients that are currently being treated.
Okay. Can you comment on just how material that TAM expansion would be with the CIC data?
Sue?
Yeah, sure. Absolutely. With CIC, we know that a lot of people, it's about two to three times the size of the current IBS-C market, and we do know that a lot of those patients are treated and successfully treated with over-the-counter. By the time they would then advance into an RX, the chances are it could be around the same size of the market. In terms of the Venn diagram, they're somewhat overlapping. I think for us, the advantage of getting CIC is, you've already got IBS-C and CIC with our two major competitors. I think it's just making it easy for the physician to not have to worry about, does this person have pain or do they not have pain?
Is that dynamic something that you're seeing on the ground today in terms of doctors kind of thinking about IBSRELA as IBS-C and then not necessarily using it, selecting it, because it doesn't have as broad of a label as some of the competitors?
I think right now you have to think about it, right? Is the issue, right? If I come into your office and I have CIC, you're going to either have to fight for an off-label approval and a difficult PA process already, or you're going to have to have me be an ICD-10 code for IBS-C. What it does is actually gets rid of having to think about it, where your patients with CIC or IBS-C would be able to utilize IBSRELA.
Okay. So, talk about the different things that happened this year around IBSRELA guidance. You guys lowered guidance on Q2, then you reiterated on Q3, which is great. Just talk about what some of those dynamics were that you saw in Q2.
Yeah, I mean, so we did take a call down in IBSRELA in Q2. Really, when we started to see some of the payer friction start to happen or really start to come to fruition towards the middle of and the end of Q2, we knew it was prudent that we had to take the guidance down. The initial guidance would have suggested IBSRELA growth this year of like mid-50% range, which in the beginning of the year, we felt like, yes, coming off of a 73% growth, that that was going to be reasonable. So we did take that step down. We now guided to $250 million-$270 million. Really happy to say, we still reiterated that in Q3, and that will be growth in the 30% range. So, we feel very good about that, and that is going to put us on a great trajectory as we move into 2027.
With XPHOZAH, we also reiterated the guidance that we had put out in the beginning of the year, $110 million-$120 million. So again, that is a contributor, and it will remain that way.
Sure. You mentioned friction on the payer level, so maybe give a little bit more color in terms of what you are actually seeing, how that is impacting prescriptions from being filled, and then what you guys are doing about it.
Just to start is, as we've mentioned, I think at our earnings call and in meetings that we've been having, starting the fourth quarter last year, a dynamic began to shift in the IBS-C and CIC market, where one of our competitors, LINZESS, cut their WAC price in half. That changed the dynamics as payers saw a drug that was growing 73%. Pressures began to be imposed upon our patients and the HCPs that are fighting for those prior authorizations. That's the friction we speak of. I think it's important that we note that there are very few examples of a drug like IBSRELA being forbidden from being filled. What they're doing is causing more work to be done in order to get that prescription fulfilled for the patient.
Our work now is to help the offices that are working through these prior authorizations to know how to fight those fights and take the battle to the payers to justify the prescription being filled. That prior authorization process is the friction we speak of, that our FRMs are integral to helping those offices understand how to navigate the process.
Mm-hmm. What does a typical PA process look like today for IBSRELA?
There isn't one typical one. They range from all payers are going to have different requirements. It can be as simple as an attestation, where you as my physician would say, "Mike has IBS-C. He has had it on previous medications," and a prescription gets filled. There are others that say, "You need to show the Rome criteria for IBS-C," which is pain and constipation, or documentation. It depends upon the payer. They all have different requirements. There isn't one necessarily answer to a typical approach.
Mm-hmm. Okay. What has been the feedback so far from these field reimbursement managers that you guys have put in the field?
So a couple things, and Sue, please comment as well, is in these offices, they are very accustomed to, on the biologic side, working through prior authorizations. It's a muscle that an office needs to be able to exercise, know what they need to do in certain payers and what's required of them. For IBS-C indicated medications, it's been primarily retail prescription, so you've not had to do prior authorizations. So it's changing of hearts and minds within an office to understand what it is that's required to get a specialty-like drug that IBSRELA is, which is relegated to second or third line, which we're thrilled with, to understand the process that needs to be there. It's more about muscle memory
getting people accustomed to what it is that needs to be accomplished in order to get a PA through.
Okay. From a demand perspective, there's nothing wrong with demand, right?
No.
The top of the funnel is still
Absolutely
robust.
Yeah.
Okay. A very common question that we get is, how to think about IBSRELA in 2027, right? You guys have incrementally talked about contracting with payers, and that leads to people trying to understand what gross to net will look like next year, right? Can you just help remind us, the latest messaging around that for 2027?
Yeah, I will start, but feel free to add in. Normally, we come out usually pre-JPMorgan to do what our-
guidance looks like for the year. What I would say is, we still very much feel like sales are going to be on a growth trajectory and continue that way like they did this year. OPEX is going to be, we have leveled out in a good place, which is also why we have declared profitability for 2027.
That's the first thing. I'd say in terms of what you're looking at, engaging with payers, these are processes, and they aren't necessarily kind of a big bang or a big step forward. We're going to take incremental steps as appropriate, and I think as appropriate really means, it's got to be able to be ROI positive for us. When you think about just doing that, there are plenty of steps to take, not only with the FRMs, but also contracting just being a vehicle, one of the vehicles that we're approaching this with.
I think we embarked on something this year that it was the first time for us, is direct-to-patient, direct-to-consumer advertising. What's important about this is, in our market research before we kicked this off, we found that when patients were shown our ad, which is streamed to Hulu, Prime, TV, things like that, versus linear TV, that those patients, 80%-90% of them, would ask for IBSRELA. That's a really important part of the demand growth that we're going to create in the top of the funnel. We know that there's a huge increase in eyeballs that are going to our consumer website for IBSRELA. That is one of the proof points that that ad is actually having the impact. What's really important then is if I go into you as a physician and say, "Hey, I saw this.
I'm dissatisfied with my current medication," you as a physician are 70% or greater likely to grant that prescription to drive the top of the funnel utilization or demand.
It's both the FRMs at the bottom of the funnel to help pull those through and get them fulfilled, but at the same time, driving significant demand at the top of the funnel. You must do both.
Yeah, Dennis, the only thing I would add is, you asked about GTN. We are in a pretty favorable rate in terms of GTN. This quarter was about 32%. When you think about it, a lot of large pharmas are really the opposite of that. They get to keep 30%, where we actually have a pretty strong headroom there. Not that we want to use it, but we definitely have, we are in a more advantaged situation there in terms of our GTN rate. We also do have a patent that goes pretty far out that we can certainly talk about as well, but we want to be sure we are preserving as much of that as we continue to move forward.
I think it is really important to highlight that it is not going to be like a one-time step function.
Correct
in terms of gross to net.
No, Dennis, we have to be very disciplined in this, right? It is a one-way street once you start giving up margin.
For us, we need to have, certainly Sue and I, as we talk to our market access teams, we need to see that there is going to be a return in that investment. Any margin we give up is an investment. Just like SG&A, it is an investment to get a return. We need to see that there is going to be a benefit in facilitating the process. We are never going to be first line, so we should all understand that this is going to be a second or third line medication. It is the choice that we made. It is the right thing to do because we preserve that margin. Our job now is to incrementally, over time, facilitate an easier path through that funnel, because opening the floodgate is not going to work.
If you look at even the IRA negotiated price and where those other medications are going to over the next one to two years, there is a likelihood that the market is to expand as a result of those lower prices. So we are going to be in an incredibly important position as a second and third line, the only share of voice in the market, for where we call. So patience is what we are helping people understand, is that we will make modest and incremental steps. There is not a huge floodgate or a gross net hole that we are going to create that needs to be filled. This is just a meaningful, mindful way of navigating those processes with payers.
Modest and incremental.
Yeah.
Yeah. Okay. You guys have mentioned ROI multiple times, positive ROI. So, what does that look like? How will you figure out that the kind of concessions that you are making is driving more volumes? A little bit.
Let me start, and Sue, please weigh in, is one of the most sounds silly what I'm about to say is, one of the most important things about next year, we're going to be generating free cash.
Our ability to build this enterprise, now on this engine called IBSRELA, what we've created, allows us to build a portfolio and a pipeline of other medication that this team and what it is that we can accomplish going forward. That ability, with the cash we have on our balance sheet, what it is that we're creating going forward, is such a critical time for the company as we look at business development opportunities to build this pipeline. That is the ROI, right? Giving that up means that could be delayed, and that's not the objective, right?
We want to preserve as much as what we create in order to build this enterprise.
Yeah, I'd say it's all about mindful choices that you make. You could invest in many different things, but we want to make sure we're doing the highest ROI, programs and such.
Whether it is contracting, DTC, the sales force, which is our highest ROI, and we have really invested behind that due to that fact.
Mm-hmm. On profitability-
Maybe just characterize that a little bit more. You mean full-year profitability, or maybe comment on also the magnitude, right? If you are $5 million positive, is that-
Positive is positive.
like a big win? Just help us understand that.
Yeah, I mean, stay tuned. Profitability is just that, and I know a lot of companies do non-GAAP, and ex-SBC were profitable, and we are too, b ut I am choosing, and we are choosing to say, we want to be GAAP profitable. That is what we are striving for, and we have high confidence we are going to do for next year. Again, I think it really is a testament to everything that we have done, the company has done to really get XPHOZAH and IBSRELA on a great growth trajectory, particularly IBSRELA.
Mm-hmm. Okay. Can you talk about the durability of the IBSRELA franchise, right? You guys talked about the patents, so maybe-
Yeah
go into a little bit more detail there. But you guys have said it is a billion dollars in peak sales and 20 whatever, but just help us understand, like, where you see the IP going.
I mean, two things. From a macro perspective, and certainly even with CIC, gives us that much more confidence. As you look at 7 million-8 million prescriptions this year being written for IBS-C indicated medications, it has historically grown high single digits, low double digits year-over-year since LINZESS was launched. They created this market. There's no reason to believe that that growth isn't going to continue since 7 million-8 million prescriptions mathematically says, 2 million-3 million people. Between the two populations, there's anywhere from 10 million-20 million people that would benefit from these medications. The opportunity is massive, right? 70% of those patients need alternatives. There's only one alternative after all of those, and it's IBSRELA. How we capture that is our job, right?
The top of the funnel, the pull-through, some of these incremental and modest things that we do with payers to facilitate the path through, gives us the confidence in our ultimate reach of that. I'll ask Sue to comment why we backed off the timing for the billion, because it just made sense mathematically. It doesn't in any way change our conviction that the billion is absolutely there for us.
I liked what you said, the 20 million whatever.
Yeah
That's kind of what we did, is we decoupled the timing. That was really just given where we were from our compound growth rate. We have total confidence we're going to get there. It's just really a matter of when. Is it an extra six months, a year? Whatever it is, we're definitely going to get there. We obviously have a long patent life to be able to continue to grow from there.
Do you feel like you will be able to get there with the sales force that you have today, or would you think about expanding that? And if so, at what time, or at what point would you consider
I mean, if you look at the dynamics of it's 200,000 physicians roughly write IBS-C indicated medications. We're not calling on all of them, right? From the outset when we launched IBSRELA, we chose to call on 50%, which is only 14,000 HCPs.
You need 144 salespeople out there, roughly 100 HCPs per salesperson. And that's it. Might we, around the edges, add some? Probably, b ut it's not going to be a wholesale shift in the number of people that we have, because it's a dilutive effort to try to call on those 182,000, 185,000 remaining physicians rather than focusing on the top 50%.
When CIC launches, there might be a small incremental, but nothing, as Mike said
Yeah
like wholesale change or addition.
Okay. Then on the Field Reimbursement Manager perspective, you guys added, I want to say 15-20?
20.
20.
Right. So, is that where you want it to be, especially given some of this friction that you are seeing with the access?
That is certainly a place where we could imagine optimizing more. But it is not going to be hundreds of people, right? I mean, if you-
Sure
you look at the sort of the ratio of salesperson to FRM, there's a ratio that's optimal, and maybe there we'll do some incremental investment. I think when Sue joined us just over a year ago, we have a capital allocation strategy now, right? We look, and ROI positive is a fundamental part of that capital allocation strategy that we have. Any of these adds are going to have to be justified by a business case that makes sense to include any of those additional expenses.
Mm-hmm. Okay. And then, excuse me, as you're thinking about 2027, what kind of learnings will you make from 2026 that you would apply to 2027, and how should we think about growth in the franchise next year?
Yep. I guess I would start, I was smiling just because I also think we need to ensure that we come out with conservative guidance. Coming out and having to kind of re-guide in second quarter is not something I want to have to do again. When I think about learnings this year, it's really about that, and just ensuring that we can really show the value that this company brings, whether it's IBSRELA, XPHOZAH, the new pipeline assets that we continue to have within CIC, and potential other ones in BD.
I think the other thing for me is the benefit that IBSRELA is providing these patients. On average, it takes six to eight years for someone to be diagnosed with IBS-C, and it's a difficult journey. 80% of patients with IBS-C are women of childbearing years, and to spend six to eight years not being able to participate in family activities and having significant impediment in terms of normal life is a significant issue, right? What we know is the durability of our competitors, four to five scripts a year, whether it's tachyphylaxis or drug holidays because things are working and they take a break, we're seeing with IBSRELA five to six. So, we're already seeing that patients are more durable, arguably because of the benefit it's providing.
That's a critically important thing for us in this business, is that we want to impart a benefit to the patients that we serve. What we're learning since launch is that, in fact, IBSRELA is providing that very differentially than other products that have been out there. So, the expansions that we do, the work we do to get more patients on therapy, the fights that we have to get patients through the prior authorization process is all part of the job. Moving our patients into the IBSRELA Pharmacy Network is a fundamental part of that, which we've talked about in the past, where if you go to a retail pharmacy, 90%- 95% of the scripts filled in CVS, Walgreens retail are generic. Any diversion away from filling a generic prescription to a prior authorization is folly, right?
Had we to do it over again, I probably would have launched with only a pharmacy network and not retail. So, making sure that the services underlying the support for the patients are as robust as they need to be to make sure that they get the drugs that they've been prescribed.
Are you seeing the benefit of the specialty pharmacy as it relates to refills today?
On average, we see one to two additional scripts per annum that go through the IPN, right? Because it's higher touch.
The reminders that go out that you need to refill, all those things are sort of self-fulfilling, virtuous cycles.
Going through the pharmacy network, both from the first prior authorization to refills, all those things are better through the IPN.
Okay. To put the one to two into a little bit more, I guess, context, right? A patient typically gets four to five scripts a year.
That's right.
Right? So, one to two is actually pretty meaningful.
It's meaningful.
It's 20%-30% more.
Yeah.
Absolutely.
Okay. Perfect. Let's talk about XPHOZAH real quick. How should we think about the growth profile of that next year? Meaning, should we expect growth? Should it be stable?
Yeah, let me make an opening comment on it, is this company was founded in 2007 around the idea of trying to find better medicines for patients on dialysis. That was the fundamental idea here. It was near and dear to my heart and back to my career at Genzyme to do this. It's an incredibly difficult business given the reimbursement environment for dialysis patients. We are committed to having XPHOZAH continue to be a contributor. It's not in and of itself the company maker. IBSRELA is the engine that's going to drive the expansion of the company, business development opportunities, and the cash generation that we've spoken of. But we will ensure that it's a contributor.
Mm-hmm. Absolutely.
Okay. Can you talk a little bit about the pipeline?
Sure.
Yes.
Yeah, just like where are we on that, and have you guys figured out where exactly you're going to position that molecule?
Yeah, we have CIC currently in phase III. We just completed enrollment a couple months earlier than expected. We will have data readout second half of next year, and then beyond that, filing. That is the first one. We have a number of pediatric trials ongoing, continued investment in the R&D area. Then we have a preclinical RDX10531 that we are just doing some IND enabling right now. Obviously looking for other things in terms of inorganic growth, like is there anything else out there within our therapeutic areas or otherwise?
Fundamentally, with that thing called free cash on the horizon, is a wonderful concept where, from a business development standpoint, our ability to build a pipeline through partnering acquisition is part and parcel of how we grow this enterprise. The business development strategy for the company is critical as we grow and build that pipeline and leverage the infrastructure that we have built for CIC pediatrics and the capabilities that we have.
We are also in a strong cash position to kind of look at some of those earlier assets now with $285 million of cash on the balance sheet as of the end of September, and growing. All good there too.
Okay. In the last minute or two, just talk briefly around, once you get to cash flow positivity and you guys are scouring the landscape for assets, what would be an ideal type of asset for you guys to bring in, and what phase?
Yeah, right now it's what we can afford, right? That is an incredibly important lens that we look at things today. We can scale into both developing those things, be they successful in the early development, and we can scale into being able to afford bigger opportunities in the not-too-distant future. So that's a critically important part. It's natural to look in our therapeutic areas. That's the step one, right? So we know the areas, we know all the issues around both renal and GI. Sadly, I think the probability of doing something in dialysis is diminished
significantly for the reasons we know. But then you look at adjacencies. What are those things? Hepatology is an interesting example. That's an adjacency to GI. However, if you look at the history of our industry, opportunism in looking outside of your initial therapeutic areas is the way companies are built. Every member of this management team has joined me in order to build this company, all of whom have many, many different therapeutic areas in which they've been. So we are agnostic and open-minded, but very judicious in the things that we look at outside of our current therapeutic areas.
Sure. Okay. Well, I think that's all the time that we have right now, but it's great to see you guys, and yeah, I hope you guys have a great conference.
Thank you, Dennis. Appreciate it.
Thank you. All right.